目的 分析復(fù)方苦參注射液聯(lián)合納武利尤單抗注射液治療晚期非小細(xì)胞肺癌患者的臨床效果。方法 選取2020年1月—2021年12月無(wú)錫市中醫(yī)醫(yī)院收治的100例晚期非小細(xì)胞肺癌患者，根據(jù)患者的治療方案將患者分為對(duì)照組和治療組，每組各50例。對(duì)照組給予納武利尤單抗注射液3 mg/kg，靜脈輸注60 min,2周用藥1次；治療組在對(duì)照組基礎(chǔ)上第1～14天靜脈滴注復(fù)方苦參注射液20 mL，與0.9%氯化鈉注射液200 mL充分混合。21 d為1個(gè)周期，兩組患者均連續(xù)治療3個(gè)周期。比較兩組的臨床療效、生活質(zhì)量、腫瘤標(biāo)志物水平變化、不良反應(yīng)和生存情況。結(jié)果 治療組的客觀緩解率、疾病控制率高于對(duì)照組（P<0.05）。治療后，兩組的Karnofsky功能狀態(tài)評(píng)分標(biāo)準(zhǔn)（KPS）評(píng)分均升高（P<0.05），治療組的KPS評(píng)分高于對(duì)照組（P<0.05）。治療后，兩組的血清細(xì)胞角蛋白19片段抗原21-1(CYFRA21-1)、神經(jīng)元特異性烯醇化酶（NSE）、癌胚抗原（CEA）水平均顯著降低（P<0.05），治療組的血清CYFRA21-1、NSE、CEA水平低于對(duì)照組（P<0.05）。治療組疲勞、胃腸道反應(yīng)發(fā)生例數(shù)少于對(duì)照組（P<0.05）。治療組的中位無(wú)進(jìn)展生存期、總生存期長(zhǎng)于對(duì)照組（P<0.05）。結(jié)論 復(fù)方苦參注射液聯(lián)合納武利尤單抗注射液治療晚期非小細(xì)胞肺癌可獲得較好的臨床效果，對(duì)改善生活質(zhì)量、降低腫瘤標(biāo)志物水平有積極作用，還可以延長(zhǎng)患者生存時(shí)間、降低不良反應(yīng)。

Objective To analyze the clinical efficacy of Compound Kushen Injection combined with Navolizumab Injection in treatment of advanced non-small cell lung cancer. Methods 100 Patients with advanced non-small cell lung cancer admitted to Wuxi Hospital of Traditional Chinese Medicine from January 2020 to December 2021. Patients were divided into control group and treatment group based on their different treatment plans, with 50 patients in each group. Patients in the control group were given Navulizumab Injection 3 mg/kg, intravenous infusion for 60 min, once every 2 weeks. Patients in the treatment group were iv administered with 20 m L Compound Kushen Injection on the basis of the control group, from first day to 14^th day, which was thoroughly mixed with 200 m L 0.9% sodium chloride injection. One course had 21 days, and both groups of patients were treated continuously for three courses. The clinical efficacy, quality of life, changes in tumor marker levels, adverse reactions, and survival status were compared between two groups. Results The objective remission rate and disease control rate of the treatment group were higher than those of the control group（P＜0.05）. After treatment, KPS scores of both groups were significantly increased（P＜0.05）, and KPS scores of the treatment group were higher than those of the control group（P＜0.05）. After treatment, the levels of serum CYFRA21-1, NSE, and CEA in both groups were significantly reduced（P＜0.05）, and the serum levels of CYFRA21-1, NSE, and CEA in the treatment group were lower than those in the control group（P＜0.05）. The incidence of fatigue and gastrointestinal reactions in the treatment group was lower than that in the control group（P＜0.05）. The median progression free survival and overall survival of the treatment group were longer than those of the control group（P＜0.05）. Conclusion The combination of Compound Kushen Injection and Navulizumab Injection can achieve good clinical effects in treatment of advanced non-small cell lung cancer, which has a positive effect on improving quality of life, reducing tumor marker levels, prolonging patient survival, and reducing adverse reactions.

R979.1

國(guó)家重點(diǎn)計(jì)劃研發(fā)項(xiàng)目(2018YFC1705102)